This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The study was a randomised controlled trial. The method of randomisation was not reported. Follow-up was for 9 months, although data on the use of National Health Service (NHS) resources were collected for an additional 3 months for the purpose of sensitivity testing. There was no loss to follow-up. Of the total sample, 257 patients in the GP with special interest group and 155 in the hospital outpatient group provided data on one of the primary outcome measures, namely the change in the dermatology life quality index. Data on the other primary outcome measure (i.e. accessibility of care) were provided by 266 patients in the GP with special interest group and 125 hospital outpatients.
Analysis of effectiveness
The primary health outcome used in the analysis was the change in the dermatology life quality index and accessibility of the service (based on 3 questions concerning access and scored from 0 to 100). The secondary outcomes included patient satisfaction with the consultation, satisfaction with the facilities, attendance rates and waiting times. The analysis of effectiveness was based on data from those completing the dermatology life quality index questionnaire and access scales. Data on the comparability of the groups at baseline were not provided.
Effectiveness results
The gain in dermatology life quality index score was 2.54 (95% confidence interval, CI: 2.0 to 3.8) in the GP practice with special interest group and 2.36 (95% CI: 1.62 to 3.10) in the hospital outpatient group. The difference between the two scores was 0.18.
In the GP with special interest group, the outcomes were: satisfaction on the access scale, 76. 
Clinical conclusions
The GP with special interest service provided improved access whilst providing broadly similar health outcomes.
Measure of benefits used in the economic analysis
The authors used both the dermatology life quality index and composite access score.
Direct costs
The costs included in the analysis were those of the NHS. These included hospital, consultant, GP with special interest service, GP, district nurse, diagnostic tests, investigations and treatments, drugs, travel and costs. Resource use and costs were estimated using data from the study; these data were reported separately. The resource use data were assessed through a questionnaire administered 6 weeks after the first appointment. Discounting was not carried out, but it was not relevant given the short time horizon. The dates when the study was carried out and the quantities measured were
